{ }
001122334455554433221100
001122334455554433221100

UBS maintains buy rating for Microsoft with target price of 510 dollars

UBS maintains a 'Buy' rating for Microsoft with a price target of $510, following a recent company visit. Analyst Karl Keirstead noted concerns over the sluggish growth of the Azure cloud platform, which may impact shares in the short term, but long-term growth drivers remain strong. Microsoft has seen a 315% increase since its initial recommendation.

UBS maintains buy rating for Hermes with target price of 2475 euros

UBS has maintained its "Buy" rating for Hermès, setting a target price of 2,475 euros, following the luxury goods group's strong fourth-quarter performance that exceeded expectations. Analyst Zuzanna Pusz highlighted the company's unique business model and the positive industry trend benefiting only a select few players. Hermès has seen a 50% increase since its initial recommendation.

UBS raises Adyen price target to 2050 euros maintaining buy rating

UBS has increased its price target for Adyen from 1800 to 2050 euros, maintaining a "Buy" rating following strong half-year results. Analyst Justin Forsythe noted that a mid-20 percent sales increase in 2025 is now easily achievable for the payment processor.

UBS downgrades Novartis to neutral amid patent expiry concerns

UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline, favoring AstraZeneca as a buy instead.

UBS downgrades Novartis to neutral amid patent expiries and weak pipeline

UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in its research pipeline for 2025, favoring AstraZeneca as a better investment option.

UBS maintains sell rating for Redcare Pharmacy amid Amazon competition

UBS has maintained a "Sell" rating for Redcare Pharmacy, setting a target price of 85 euros. Analyst Olivier Calvet highlighted that Amazon's entry into the European market for non-medical beauty and care products poses a significant challenge for online pharmacies like Redcare Pharmacy and DocMorris.

UBS maintains sell rating for Siemens Energy with 38 euro target

UBS has maintained a "Sell" rating for Siemens Energy, setting a price target of 38 euros following the company's first-quarter results for 2024/25, which met expectations. Analyst Supriya Subramanian noted that Siemens Energy has made a solid start to the financial year.

UBS maintains buy rating for Deutsche Börse with 260 euro price target

UBS has maintained a "Buy" rating for Deutsche Börse with a target price of 260 euros following the release of its fourth-quarter 2024 figures. Analyst Michael Werner noted that the announced share buyback represents about one percent of the share capital, but anticipates a muted market reaction due to the quality of the quarterly results.

UBS raises AMS-Osram price target to 14 francs maintaining buy rating

UBS has increased its price target for AMS-Osram from 13.80 to 14.00 francs, maintaining a "Buy" rating following the semiconductor manufacturer's positive fourth quarter 2024 results. Analyst Harry Blaiklock noted the company's reassuring statements on cash flow as a key factor in this decision.

UBS maintains buy rating for British American Tobacco with target price of 3900 pence

UBS has maintained a 'Buy' rating for British American Tobacco (BAT) with a target price of 3900 pence ahead of the company's upcoming results. Analyst Faham Baig anticipates that the new Velo Plus nicotine pouches, featuring synthetic nicotine, will significantly boost growth in the new products segment, with high demand already noted in online retail.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.